Edwards Lifesciences (NYSE: EW) CFO nets 13K-share sale under plan

Rhea-AI Filing Summary

Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised options for 13,000 shares of common stock at $59.2567 per share on March 11, 2026, then sold all 13,000 shares in open-market transactions at weighted average prices of $84.4613 and $85.2079.

After these transactions, he holds 39,699 shares directly and 266,318 shares indirectly through a trust, so the 13,000-share sale represents a small portion of his total reported holdings. All transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on July 29, 2025, indicating they were scheduled in advance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ullem Scott B.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M(1)		13,000	A	$59.2567	52,699	D
Common Stock	03/11/2026		S(1)		5,099	D	$84.4613(2)	47,600	D
Common Stock	03/11/2026		S(1)		7,901	D	$85.2079(3)	39,699	D
Common Stock								266,318	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	03/11/2026		M			13,000	05/08/2020	05/07/2026	Common Stock	13,000	$0.0000	26,000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $83.865 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $84.865 to $85.790. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Edwards Lifesciences (EW) CFO report?

Edwards Lifesciences CFO Scott B. Ullem exercised options for 13,000 shares at $59.2567 and sold 13,000 shares in open-market trades near $84–$86. These actions form an exercise-and-sell sequence rather than a new open-market purchase.

How many Edwards Lifesciences (EW) shares does the CFO hold after this Form 4?

Following the reported transactions, the CFO holds 39,699 Edwards Lifesciences shares directly and 266,318 shares indirectly through a trust. Together, these positions show a substantial remaining stake after the 13,000-share sale reported in the filing.

Were the Edwards Lifesciences (EW) CFO’s share sales pre-planned?

Yes. The filing states all reported transactions were executed under a Rule 10b5-1 trading plan adopted on July 29, 2025. Such pre-planned arrangements typically indicate routine portfolio management rather than discretionary market-timing decisions by the insider.

What prices were involved in the Edwards Lifesciences (EW) CFO’s March 2026 trades?

The CFO exercised stock options at an exercise price of $59.2567 per share and sold 13,000 shares at weighted average prices of $84.4613 and $85.2079. The sale prices reflect multiple trades within disclosed price ranges.

Does the Edwards Lifesciences (EW) Form 4 show remaining stock options for the CFO?

The filing’s derivative section shows a 13,000-share option exercise and no remaining derivative positions listed afterward. This indicates the reported option grant tied to this transaction was fully exercised, with no additional related options shown in this Form 4.